Mokari Atabak has filed 39 insider transactions across 1 company since February 2023.
Most recent transaction: a grant/award of 397 shares of CORCEPT THERAPEUTICS INC ($CORT) on March 02, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 397 | $0.00 | 15,353.0000 | 119,981,000 | 2.65% | 0.00% |
| March 2, 2026 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 397 | $35.97 | 14,956.0000 | 119,981,000 | 2.73% | 0.00% |
| March 3, 2026 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | F | Common Stock | 96 | $35.97 | 15,257.0000 | 119,981,000 | 0.63% | 0.00% |
| Feb. 27, 2026 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Stock Option (right to buy) | 140000 | $0.00 | 140,000.0000 | 119,981,000 | 9999.99% | 0.12% |
| Dec. 1, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 178 | $79.78 | 14,499.0000 | 119,981,000 | 1.24% | 0.00% |
| Dec. 2, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | F | Common Stock | 118 | $79.78 | 14,559.0000 | 119,981,000 | 0.80% | 0.00% |
| Dec. 1, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 178 | $0.00 | 14,677.0000 | 119,981,000 | 1.23% | 0.00% |
| Sept. 3, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | F | Common Stock | 144 | $71.38 | 14,321.0000 | 113,480,000 | 1.00% | 0.00% |
| Sept. 2, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 200 | $71.38 | 14,265.0000 | 113,480,000 | 1.42% | 0.00% |
| Sept. 2, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 200 | $0.00 | 14,465.0000 | 113,480,000 | 1.40% | 0.00% |
| June 2, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 775 | $71.68 | 13,809.0000 | 113,480,000 | 5.95% | 0.00% |
| June 2, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 775 | $0.00 | 14,584.0000 | 113,480,000 | 5.61% | 0.00% |
| June 3, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | F | Common Stock | 519 | $71.68 | 14,065.0000 | 113,480,000 | 3.56% | 0.00% |
| March 3, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 232 | $59.07 | 12,802.0000 | 113,480,000 | 1.85% | 0.00% |
| March 3, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 232 | $0.00 | 13,034.0000 | 113,480,000 | 1.81% | 0.00% |
| Feb. 28, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Stock option (right to buy) | 140000 | $0.00 | 140,000.0000 | 113,480,000 | 9999.99% | 0.12% |
| March 3, 2025 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | F | Common Stock | 228 | $60.58 | 12,570.0000 | 113,480,000 | 1.78% | 0.00% |
| Dec. 2, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | F | Common Stock | 182 | $57.68 | 12,336.0000 | 113,723,000 | 1.45% | 0.00% |
| Dec. 2, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 231 | $59.21 | 12,567.0000 | 113,723,000 | 1.87% | 0.00% |
| Dec. 2, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 231 | $0.00 | 12,798.0000 | 113,723,000 | 1.84% | 0.00% |
| Sept. 3, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 400 | $0.00 | 12,518.0000 | 111,742,000 | 3.30% | 0.00% |
| Sept. 3, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 400 | $34.26 | 12,118.0000 | 111,742,000 | 3.41% | 0.00% |
| Sept. 3, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | F | Common Stock | 143 | $35.30 | 11,718.0000 | 111,742,000 | 1.21% | 0.00% |
| June 3, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | F | Common Stock | 571 | $30.17 | 8,965.0000 | 111,742,000 | 5.99% | 0.00% |
| June 3, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 1448 | $31.30 | 10,413.0000 | 111,742,000 | 16.15% | 0.00% |
| June 3, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 1448 | $0.00 | 11,861.0000 | 111,742,000 | 13.91% | 0.00% |
| March 1, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | F | Common Stock | 517 | $24.06 | 8,428.0000 | 111,742,000 | 5.78% | 0.00% |
| March 1, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 554 | $24.06 | 8,982.0000 | 111,742,000 | 6.57% | 0.00% |
| March 1, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 554 | $0.00 | 9,536.0000 | 111,742,000 | 6.17% | 0.00% |
| Feb. 9, 2024 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Stock option (right to buy) | 200000 | $0.00 | 200,000.0000 | 111,742,000 | 9999.99% | 0.18% |
| Dec. 1, 2023 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 508 | $0.00 | 8,945.0000 | 115,966,000 | 6.02% | 0.00% |
| Dec. 1, 2023 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 508 | $25.97 | 8,437.0000 | 115,966,000 | 6.41% | 0.00% |
| Sept. 1, 2023 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 398 | $33.10 | 7,806.0000 | 115,966,000 | 5.37% | 0.00% |
| Sept. 1, 2023 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 398 | $0.00 | 8,204.0000 | 115,966,000 | 5.10% | 0.00% |
| June 1, 2023 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 1651 | $0.00 | 7,408.0000 | 115,966,000 | 28.68% | 0.00% |
| June 1, 2023 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 1651 | $22.97 | 5,757.0000 | 115,966,000 | 40.21% | 0.00% |
| March 1, 2023 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 1260 | $0.00 | 4,106.0000 | 115,966,000 | 44.27% | 0.00% |
| March 1, 2023 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Common Stock | 1260 | $19.86 | 2,846.0000 | 115,966,000 | 79.45% | 0.00% |
| Feb. 13, 2023 | CORCEPT THERAPEUTICS INC | $CORT | Mokari Atabak | Chief Financial Officer | A | Stock option (right to buy) | 200000 | $0.00 | 200,000.0000 | 115,966,000 | 9999.99% | 0.17% |